Research led by Professors Jianxing He and Wenhua Liang from the First Affiliated Hospital of Guangzhou Medical University ...

The "cell of origin" of the second most common lung cancer and the way that it becomes dominant in the lung have been ...

In 2015, the First Affiliated Hospital of Guangzhou Medical University, in collaboration with the Guangdong Hetaoxiang ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Revolution Medicines, Inc. (NASDAQ:RVMD) on Sunday announced new clinical data for zoldonrasib (RMC-9805), a RAS(ON) ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...

Inhibrx Biosciences, Inc.’s INBX share price has dipped by 5.67%, which has investors questioning if this is right time to ...